AR037907A1 - Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6 - Google Patents
Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6Info
- Publication number
- AR037907A1 AR037907A1 ARP020104952A ARP020104952A AR037907A1 AR 037907 A1 AR037907 A1 AR 037907A1 AR P020104952 A ARP020104952 A AR P020104952A AR P020104952 A ARP020104952 A AR P020104952A AR 037907 A1 AR037907 A1 AR 037907A1
- Authority
- AR
- Argentina
- Prior art keywords
- optionally substituted
- independently
- aryl
- alkyl
- alkyl group
- Prior art date
Links
- 239000003446 ligand Substances 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 8
- 125000001072 heteroaryl group Chemical group 0.000 abstract 6
- 125000003118 aryl group Chemical group 0.000 abstract 5
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 3
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 3
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 3
- -1 cycloheteroalkyl Chemical group 0.000 abstract 3
- 125000005842 heteroatom Chemical group 0.000 abstract 3
- 229910052760 oxygen Inorganic materials 0.000 abstract 3
- 229910052717 sulfur Inorganic materials 0.000 abstract 3
- 125000004429 atom Chemical group 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- 108091005435 5-HT6 receptors Proteins 0.000 abstract 1
- 101100173726 Arabidopsis thaliana OR23 gene Proteins 0.000 abstract 1
- 125000002619 bicyclic group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000003107 substituted aryl group Chemical group 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
El uso del mismo para el tratamiento terapéutico de trastornos relacionados con, o afectados, por el receptor de 5-HT6. Reivindicación 1: Un compuesto de fórmula (1), en donde: W es SO2, CO, CONR11 o CSR12; X es N o CR1; Y es N o CR2; Z es N o CR3; Q es N o CR4, con la condición de que no más de dos de X, Y, Z y Q pueden ser N; n es un entero de 2 o 3; R1, R2, R3 y R4 son cada uno, de manera independiente, H, halógeno, CN, OCO2R13, CO2R14, CONR15R16, CNR17NR18R19, SOmR20, NR21R22, OR23, COR24, o un grupo alquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-6, cicloheteroalquilo, arilo o heteroarilo, cada uno opcionalmente sustituido; R5 y R6 son cada uno independientemente H o un grupo alquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-6, cicloheteroalquilo, arilo o heteroarilo, cada uno opcionalmente sustituido; o R5 y R6 se pueden tomar junto con el átomo al cual están unidos, para formar un anillo de 5 a 7 miembros opcionalmente sustituido, que de manera opcional contiene un heteroátomo adicional seleccionado entre O, N o S; R7 y R8 son cada uno de manera independiente, H o un grupo alquilo C1-6 opcionalmente sustituido; R9 es H, halógeno, o un grupo alquilo C1-6, alcoxi C1-6, arilo o heteroarilo, cada uno opcionalmente sustituido; R10 es un grupo arilo, heteroarilo o alquilo C1-6, opcionalmente sustituido, o un sistema de anillo bicíclico o tricíclico de 8 a 13 miembros opcionalmente sustituido que tiene un átomo N en la cabeza de puente y que opcionalmente contiene 1, 2 o 3 heteroátomos adicionales seleccionados entre N, O o S, con la condición de que cuando Q es N y X, Y y Z son CH, entonces R10 debe ser diferente de fenilo; m es 0 o un entero de 1 o 2 ; R11 y R12 son cada uno de manera independiente, H o un grupo alquilo C1-6, arilo o heteroarilo, cada uno opcionalmente sustituido; R13, R14, R20 y R24 son cada uno de manera independiente H, o un grupo alquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-6, cicloheteroalquilo, arilo o heteroarilo, cada uno opcionalmente sustituido; R15, R16 y R23 son cada uno de manera independiente H, o un grupo alquilo C1-6 opcionalmente sustituido; y R17, R18, R19, R21 y R22 son cada uno de manera independiente H, o un grupo alquilo C1-4, opcionalmente sustituido; o R21 y R22 se pueden tomar junto con el átomo al cual están unidos para formar un anillo de 5 a 7 miembros que opcionalmente contiene otro heteroátomo seleccionado entre O, N o S; o los estereoisómeros del mismo o las sales farmacéuticamente aceptables del mismo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34283801P | 2001-12-20 | 2001-12-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR037907A1 true AR037907A1 (es) | 2004-12-22 |
Family
ID=23343489
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP020104952A AR037907A1 (es) | 2001-12-20 | 2002-12-18 | Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6 |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US6800640B2 (es) |
| EP (1) | EP1456206B1 (es) |
| JP (1) | JP4339123B2 (es) |
| KR (1) | KR20040077861A (es) |
| CN (1) | CN1620455A (es) |
| AR (1) | AR037907A1 (es) |
| AT (1) | ATE396191T1 (es) |
| AU (1) | AU2002360618B2 (es) |
| BR (1) | BR0215151A (es) |
| CA (1) | CA2470832C (es) |
| CO (1) | CO5590960A2 (es) |
| DE (1) | DE60226775D1 (es) |
| DK (1) | DK1456206T3 (es) |
| ES (1) | ES2305338T3 (es) |
| IL (1) | IL162242A0 (es) |
| MX (1) | MXPA04005886A (es) |
| NO (1) | NO20043099L (es) |
| PL (1) | PL370890A1 (es) |
| RU (1) | RU2004122094A (es) |
| TW (1) | TW200301251A (es) |
| WO (1) | WO2003053970A1 (es) |
| ZA (1) | ZA200405733B (es) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2222828B1 (es) | 2003-07-30 | 2006-04-16 | Laboratorios Del Dr. Esteve, S.A. | Derivados de 1-sulfonilindoles, su preparacion y su aplicacion como medicamentos. |
| US7592340B2 (en) | 2003-12-04 | 2009-09-22 | Vertex Pharmaceuticals Incorporated | Quinoxalines useful as inhibitors of protein kinases |
| UY28945A1 (es) | 2004-06-09 | 2006-01-31 | Glaxo Group Ltd | Derivados de pirrolopiridina |
| MX2007002076A (es) * | 2004-09-03 | 2007-03-29 | Yuhan Corp | Derivados de pirrolo [3,2-c] piridina y procesos para su preparacion. |
| KR100958830B1 (ko) * | 2004-09-03 | 2010-05-24 | 주식회사유한양행 | 피롤로[2,3-ｃ]피리딘 유도체 및 그의 제조방법 |
| KR101142363B1 (ko) | 2005-06-27 | 2012-05-21 | 주식회사유한양행 | 피롤로피리딘 유도체를 포함하는 항암제 조성물 |
| EP1947085A1 (en) * | 2007-01-19 | 2008-07-23 | Laboratorios del Dr. Esteve S.A. | Substituted indole sulfonamide compounds, their preparation and use as medicaments |
| AU2008254588B2 (en) * | 2007-05-21 | 2013-01-17 | Sgx Pharmaceuticals, Inc. | Heterocyclic kinase modulators |
| MX2009012471A (es) * | 2007-05-24 | 2010-02-24 | Memory Pharm Corp | Compuestos 4´sustituidos que tienen afinidad al receptor 5-hidroxitriptamina 6. |
| US20100016297A1 (en) * | 2008-06-24 | 2010-01-21 | Memory Pharmaceuticals Corporation | Alkyl-substituted 3' compounds having 5-ht6 receptor affinity |
| US20100022581A1 (en) * | 2008-07-02 | 2010-01-28 | Memory Pharmaceuticals Corporation | Pyrrolidine-substituted azaindole compounds having 5-ht6 receptor affinity |
| US20100029629A1 (en) * | 2008-07-25 | 2010-02-04 | Memory Pharmaceuticals Corporation | Acyclic compounds having 5-ht6 receptor affinity |
| UA103195C2 (uk) | 2008-08-11 | 2013-09-25 | Глаксосмитклайн Ллк | Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань |
| US20100056531A1 (en) * | 2008-08-22 | 2010-03-04 | Memory Pharmaceuticals Corporation | Alkyl-substituted 3' compounds having 5-ht6 receptor affinity |
| EP2356116A1 (en) * | 2008-11-20 | 2011-08-17 | OSI Pharmaceuticals, Inc. | Substituted pyrroloý2,3-b¨-pyridines and-pyrazines |
| US8119683B2 (en) * | 2009-08-10 | 2012-02-21 | Taipei Medical University | Aryl substituted sulfonamide compounds and their use as anticancer agents |
| AR081039A1 (es) | 2010-05-14 | 2012-05-30 | Osi Pharmaceuticals Llc | Inhibidores biciclicos fusionados de quinasa |
| US20130072495A1 (en) | 2010-05-14 | 2013-03-21 | OSI Pharmaceuticals, LLC | Fused bicyclic kinase inhibitors |
| EP2714688B1 (en) * | 2011-05-26 | 2016-02-24 | Daiichi Sankyo Company, Limited | Heterocyclic compounds as protein kinase inhibitors |
| BR112014001425A2 (pt) | 2011-07-22 | 2017-11-21 | Glaxosmithkline Llc | forma de dosagem farmacêutica, composição farmacêutica, e, composto (i) ou sal farmaceuticamente aceitável do mesmo |
| JP6196674B2 (ja) | 2012-08-24 | 2017-09-13 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ | ピラゾロピリミジン化合物 |
| AU2013348216B2 (en) | 2012-11-20 | 2016-10-13 | Glaxosmithkline Llc | Novel compounds |
| BR112015011400A8 (pt) | 2012-11-20 | 2019-10-01 | Glaxosmithkline Llc | composto, composição farmacêutica, composição de vacina, e, uso de um composto |
| KR20150085080A (ko) | 2012-11-20 | 2015-07-22 | 글락소스미스클라인 엘엘씨 | 신규 화합물 |
| CN102977094A (zh) * | 2012-11-30 | 2013-03-20 | 盛世泰科生物医药技术(苏州)有限公司 | 一种2-羟基-1,5-萘啶的合成方法 |
| EP3083588B1 (en) | 2013-12-20 | 2020-12-09 | Sunshine Lake Pharma Co., Ltd. | Aromatic heterocyclic compounds and their application in pharmaceuticals |
| US9974785B2 (en) | 2014-07-08 | 2018-05-22 | Sunshine Lake Pharma Co., Ltd. | Aromatic heterocyclic derivatives and pharmaceutical applications thereof |
| RU2725886C1 (ru) | 2017-03-30 | 2020-07-07 | ЭксДабл-Ю ЛЭБОРЕТРИЗ ИНК. | Бициклические гетероарильные производные и их получение и применение |
| WO2023034645A2 (en) | 2021-09-03 | 2023-03-09 | Alexander Shulgin Research Institute | Asymmetric allyl tryptamines |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5977131A (en) | 1997-04-09 | 1999-11-02 | Pfizer Inc. | Azaindole-ethylamine derivatives as nicotinic acetylcholine receptor binding agents |
| US6100291A (en) * | 1998-03-16 | 2000-08-08 | Allelix Biopharmaceuticals Inc. | Pyrrolidine-indole compounds having 5-HT6 affinity |
| GB9820113D0 (en) * | 1998-09-15 | 1998-11-11 | Merck Sharp & Dohme | Therapeutic agents |
| CA2370147C (en) * | 1999-04-21 | 2009-07-28 | Allelix Biopharmaceuticals Inc. | Piperidine-indole compounds having 5-ht6 affinity |
| DE60011269T2 (de) * | 1999-08-12 | 2005-06-23 | Nps Allelix Corp., Mississauga | Azaidole mit serotonin rezeptor affinität |
| US6476034B2 (en) | 2000-02-22 | 2002-11-05 | Bristol-Myers Squibb Company | Antiviral azaindole derivatives |
| UA78536C2 (en) * | 2001-12-20 | 2007-04-10 | Wyeth Corp | Indolylalkylamine derivatives as ligands of 5-hydroxytryptamine-6, method of production (variants), pharmaceutical composition |
| RU2007122450A (ru) * | 2004-12-14 | 2009-01-27 | Вайет (Us) | Применение агониста рецептора 5-нт6 для лечения и профилактики нейродегенеративных заболеваний |
-
2002
- 2002-12-04 TW TW091135173A patent/TW200301251A/zh unknown
- 2002-12-17 MX MXPA04005886A patent/MXPA04005886A/es active IP Right Grant
- 2002-12-17 PL PL02370890A patent/PL370890A1/xx unknown
- 2002-12-17 CA CA2470832A patent/CA2470832C/en not_active Expired - Fee Related
- 2002-12-17 DE DE60226775T patent/DE60226775D1/de not_active Expired - Lifetime
- 2002-12-17 EP EP02795890A patent/EP1456206B1/en not_active Expired - Lifetime
- 2002-12-17 CN CNA02828173XA patent/CN1620455A/zh active Pending
- 2002-12-17 AT AT02795890T patent/ATE396191T1/de not_active IP Right Cessation
- 2002-12-17 AU AU2002360618A patent/AU2002360618B2/en not_active Ceased
- 2002-12-17 ES ES02795890T patent/ES2305338T3/es not_active Expired - Lifetime
- 2002-12-17 RU RU2004122094/04A patent/RU2004122094A/ru not_active Application Discontinuation
- 2002-12-17 IL IL16224202A patent/IL162242A0/xx unknown
- 2002-12-17 KR KR10-2004-7009710A patent/KR20040077861A/ko not_active Withdrawn
- 2002-12-17 DK DK02795890T patent/DK1456206T3/da active
- 2002-12-17 BR BR0215151-0A patent/BR0215151A/pt not_active IP Right Cessation
- 2002-12-17 JP JP2003554686A patent/JP4339123B2/ja not_active Expired - Fee Related
- 2002-12-17 WO PCT/US2002/040220 patent/WO2003053970A1/en not_active Ceased
- 2002-12-18 AR ARP020104952A patent/AR037907A1/es not_active Application Discontinuation
- 2002-12-19 US US10/323,263 patent/US6800640B2/en not_active Expired - Fee Related
-
2004
- 2004-06-15 CO CO04055770A patent/CO5590960A2/es not_active Application Discontinuation
- 2004-07-19 ZA ZA200405733A patent/ZA200405733B/en unknown
- 2004-07-19 NO NO20043099A patent/NO20043099L/no not_active Application Discontinuation
- 2004-08-19 US US10/922,678 patent/US7297705B2/en not_active Expired - Fee Related
-
2007
- 2007-11-16 US US11/941,479 patent/US7585876B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US7297705B2 (en) | 2007-11-20 |
| PL370890A1 (en) | 2005-05-30 |
| CA2470832C (en) | 2010-09-21 |
| AU2002360618B2 (en) | 2009-01-08 |
| US7585876B2 (en) | 2009-09-08 |
| KR20040077861A (ko) | 2004-09-07 |
| DK1456206T3 (da) | 2008-09-08 |
| US6800640B2 (en) | 2004-10-05 |
| US20030171395A1 (en) | 2003-09-11 |
| WO2003053970A1 (en) | 2003-07-03 |
| TW200301251A (en) | 2003-07-01 |
| DE60226775D1 (de) | 2008-07-03 |
| RU2004122094A (ru) | 2005-03-27 |
| IL162242A0 (en) | 2005-11-20 |
| US20050020598A1 (en) | 2005-01-27 |
| ZA200405733B (en) | 2005-10-19 |
| EP1456206A1 (en) | 2004-09-15 |
| BR0215151A (pt) | 2004-10-19 |
| ES2305338T3 (es) | 2008-11-01 |
| ATE396191T1 (de) | 2008-06-15 |
| CO5590960A2 (es) | 2005-12-30 |
| CN1620455A (zh) | 2005-05-25 |
| CA2470832A1 (en) | 2003-07-03 |
| NO20043099L (no) | 2004-08-17 |
| EP1456206B1 (en) | 2008-05-21 |
| US20080114023A1 (en) | 2008-05-15 |
| JP4339123B2 (ja) | 2009-10-07 |
| MXPA04005886A (es) | 2004-09-13 |
| AU2002360618A1 (en) | 2003-07-09 |
| JP2005519046A (ja) | 2005-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR037907A1 (es) | Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6 | |
| AR040566A1 (es) | Derivados de 1-heterociclilalquil 3- sulfonilazaindol o azaindazol como ligandos de 5 hidroxitriptamina-6 | |
| AR040567A1 (es) | Derivados de 1- heterociclilalquil 3- sulfonilindol o -indazol como ligandos de 5- hidroxitriptamina -6 | |
| AR037906A1 (es) | Derivados de indolilalquilamina como ligandos de 5-hidroxitriptamina-6 | |
| AR043180A1 (es) | Derivados de heterociclil-3-sulfonilazaindol o -azaindazol como ligandos de 5-hidroxitriptamina-6 | |
| AR034203A1 (es) | Derivados de 1-aril- o 1-alquilsulfonilbenzazol como ligandos de 5-hidroxitriptamina-6, un metodo para su preparacion, composicion farmaceutica y el uso de los mismos para la fabricacion de un medicamento | |
| AR037489A1 (es) | Quinolinas sustituidas y proceso para su preparacion | |
| AR040047A1 (es) | 1-(aminoalquil)-3-sulfonilazaindoles como ligandos de la 5-hidroxitriptamina-6 | |
| AR035235A1 (es) | Derivados heterocicliloxi-,-tioxi- y -aminobenzazol como ligandos de 5-hidroxitriptamina-6, un procedimiento para su preparacion, composicion farmaceutica, y el uso de dichos derivados para la manufactura de un medicamento | |
| CO5650164A2 (es) | Hetrociclil-3-sulfonilindazoles como ligandos de 5-hidroxitriptamina-6 | |
| CO5721006A2 (es) | Derivados de pirazolo-quinazolina, proceso para su preparacion y su uso como inhibidores de quinasa | |
| AR061651A1 (es) | Analogos de piridina ii | |
| AR035892A1 (es) | Derivados de oxazol, proceso para su preparacion, composiciones farmaceuticas que los comprenden, y el uso de dichos compuestos en la preparacion de medicamentos | |
| AR040031A1 (es) | Compuestos de pirazol-pirimidina anilina utiles como inhibidores de cinasa y composiciones farmaceuticas que los contienen | |
| AR068413A2 (es) | Derivados 8-amino, metodos de preparacion, composiciones farmaceuticas y su uso en terapia | |
| AR055592A1 (es) | Derivados de 2-amino-5-cicloalquil-hidantoina como moduladores y/o inhibidores de la beta-secretasa(bace) | |
| PE20030062A1 (es) | Derivados aralquilsulfonil-3-(pirrol-2-ilmetiliden)-2-indolinona como inhibidores de quinasas | |
| AR053652A1 (es) | Derivados de indol como inhibidores de proteina quinasas. composiciones farmaceuticas | |
| AR040048A1 (es) | Derivados de 1-(aminoalquil)-3-sulfonilindol e indazol como ligandos de la 5-hidroxitriptamina-6 | |
| PE20020589A1 (es) | 5-espiropirimidin-2,4,6-triona como inhibidores de metaloproteinasas | |
| AR048567A1 (es) | Derivados de benzoxazinona, su preparacion y composiciones farmaceuticas. | |
| AR044614A1 (es) | Composiciones de sulfonamida que modulan la actividad del receptor de quinioquinas (ccr4) | |
| CO5680412A2 (es) | Agonistas del receptor adrenergico etilamino beta 2 sustituido con amino | |
| MXPA05007494A (es) | Nuevos compuestos. | |
| AR039988A1 (es) | Derivados de benzoxazina como moduladores de 5-ht6 y usos de los mismos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |